

MANULIFE DANA EKUITAS TEKNOLOGI KESEHATAN GLOBAL DOLAR

DEC 2022


Investment Objective

To achieve long term capital growth by investing mainly in equity securities of companies which predominant economic activities are in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology sectors, onshore and/or offshore, directly and/or through mutual fund(s).


Fund Information

Inception Date	: 18 Oct 21
Fund Size	: USD 4,050,045.44
Fund Currency	: USD
Type of fund	: Equity
Valuation	: Daily
Custodian Bank	: Bank DBS Indonesia
Annual Management Fee	: 2.50%
Net Asset Value/Unit ³⁾	: USD 1.0054
Bloomberg Code	: MATKGMU IJ

Performance Since Inception




Monthly Performance Last 3 Years



Risk Classification

Risk classification is based on type of fund.



Allocation

Equity	: 80 - 100 %
Money Market	: 0 - 20 %

Portfolio

Equity Onshore	: 0.00%
Equity Offshore	: 98.49%
Money Market	: 1.51%

Top 5 Holdings

1 BlackRock World Healthscience Fund D2 USD

Fund Performance

Performance in USD per (30/12/22)							
	1 mo	3 mo	6 mo	YTD	1 yr	3 yr ¹⁾	5 yr ¹⁾
MANTKG	0.04%	10.71%	4.66%	-4.60%	-4.60%	n/a	n/a
BM ²⁾	-1.18%	13.14%	5.47%	-5.68%	-5.68%	n/a	n/a
Yearly Performance							
	2021	2020	2019	2018	2017	2016	2015
MANTKG	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BM ²⁾	n/a	n/a	n/a	n/a	n/a	n/a	n/a

Note

- 1) Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).
- 2) The benchmark is MSCI World Health Care Index.
- 3) The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording.

Investment Manager Commentary

Global equity market was volatile in December affected by hawkish statement from The Fed and selling pressure from foreign investor in the domestic market. The Fed raised benchmark rate by 50bps to 4.50 inline with market expectation, a smaller hike compared to 75bps increment the previous months. However, statement from Fed Chair Jerome Powell emphasized that monetary tightening will not be eased in the short term and interest rate may be higher than previous expectation due to persistent inflation and strong labor sector. European central bank (ECB) has similar outlook to The Fed, where ECB sees inflation risk are primarily to the upside and expects tightening to continue in 2023. In Asia, market sentiment was supported by China Covid restriction relaxation and optimism of economic recovery in China and Asia. On the flip side, rising Covid case in China pose risk of contagion to other countries that can affect mobility and growth outlook.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequences arising from any actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, credit risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investment instruments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volatility. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicative of future performance.

Manulife Indonesia

Established in 1985, PT Asuransi Jiwa Manulife Indonesia (Manulife Indonesia) is part of Manulife Financial Corporation Group, a Canadian financial services group that operates in Asia, Canada and the United States. Manulife Indonesia offers a wide range of financial services, including life insurance, accident and health insurance, investment and pension plans to individual customers and group clients in Indonesia. Through a network of almost 11,000 employees and professional agents spread across more than 25 sales offices, Manulife Indonesia serves more than 2 million customers in Indonesia.

PT Asuransi Jiwa Manulife Indonesia is registered and supervised by the Otoritas Jasa Keuangan (OJK). To learn more about Manulife Indonesia, follow us on Facebook, Twitter, Instagram, YouTube, or visit

